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Although there is widespread interest in fractional exhaled nitric oxide (FeNO) as a non-
invasive, time and cost effective biomarker for assessing airway inflammation in chronic
obstructive pulmonary disease (COPD), its usefulness is still controversial.
We examined the FeNO levels in clinically meaningful subgroups of COPD in a group of
91 COPD patients with FEV1 17e77% of predicted. Multiple flow rates FeNO at 10, 30, 50,
100 and 200 mL/s were measured and a two-compartment model was used to estimate the
diffusion Capacity (D), alveolar NO concentration (Calv) and airway wall NO concentration
(Caw). All patients had spirometry, assessment of symptoms with questionnaires and low-dose
CT scan as well as assessment of weight and body composition. We examined the following
subgroups of COPD: Patients with 1) Severe emphysema, 2) Chronic bronchitis, 3) Frequent
exacerbations, 4) Loss of lean body mass and 5) Low fat-free mass index. We used advanced
non-linear mixed model adjusted for age and gender.
The modelled differences in D, Calv or Caw among COPD subgroups were small and not
statistically significant. The analysis showed significant effects of current smoking on Caw
and of gender on D and Calv. The results were the same if the advanced non-linear mixed
model was substituted by more standard analysis techniques.
This study questions the relevance of using FeNO as a biomarker to evaluate local inflamma-
tion in COPD and points to a need for developing novel non-invasive biomarkers for research
laboratory work and daily clinical practice.
ª 2011 Elsevier Ltd. All rights reserved.of Cardiology & Respiratory Medicine, 253, Hvidovre Hospital, Kettegaard Alle 30, 2650 Hvidovre,
); fax: þ45 3862 3716.
vh.regionh.dk (J. Vestbo).
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FeNO and COPD subgroups 1339Introduction During the study, patients were allowed to take theirChronic obstructive pulmonary disease (COPD) is a multi-
component disease, comprising emphysema in the lung
parenchyma, large central airway inflammation, mucociliary
dysfunction, and small airway structural changes.1 All these
factors contribute to a progressive inflammatory condition
characterized by poorly reversible airflow obstruction,
which is associated with substantial morbidity.2 In addition,
there is evidence that systemic inflammation and extra-
pulmonary effects are also common in COPD, although the
association between systemic inflammation and systemic
manifestations of COPD is still unclear.1,3 The degree of
airflow limitation, as measured by forced expiratory volume
in 1 s (FEV1), seems to be poorly correlated with severity of
symptoms or health-related quality of life, which makes it
difficult to improve the definition of COPD and current
disease staging systems. In addition, patients with similar
FEV1 may show very different underlying pathologies, for
example predominantly airspace disease (i.e., emphysema)
or disease of the airways, as manifested by increased airway
wall thickness.4
As a first step to better understanding COPD, finding an
easy and non-invasive way of measuring local inflammation
in COPD is essential. Fractional exhaled nitric oxide (FeNO) is
a non-invasive, time and cost effective marker of eosino-
philic airway inflammation which is widely used in asthma.5
Specific guidelines have been developed for standardized
measurements.6 However, whether FeNO can guide medical
decision making in COPD is still controversial.5 It has been
shown that FeNO levels increase significantly in a group of
COPD patients during cold weather and at onset of exacer-
bation,7 suggesting that monitoring FeNO variation in COPD
might have clinical implications.8
Identification of subgroups of COPD is currently being
intensively pursued to better understand the disease and
be able to develop novel biomarkers.9,10 Among candidate
biomarkers are markers that reflect the level of airway and
parenchymal inflammation. In our study we classified our
patients in 5 clinically meaningful subgroups of COPD; we
defined as patients with chronic bronchitis, emphysema,
frequent exacerbations, low BMI and low FFMI. We
hypothesised that FeNO is a biomarker, which can differ-
entiate between different subgroups of COPD.
Patients and methods
The current study uses a patient cohort recruited for the
ECLIPSE study, followed prospectively for 2 years. It has been
officially registered as ECLIPSE substudy and we had access to
data on study subjects from thecentralGSKECLIPSEdatabase.
The ECLIPSE study has been described elsewhere.9 A total of
91 COPD patients aged 40e75 years were recruited. All
patients had a smoking history of >10 pack-years, a post-
bronchodilator ratio between FEV1 and forced vital capacity
(FVC) <0.7 and GOLD stage II (FEV1 50e79% predicted), III
(FEV1 30e49% predicted) or IV (FEV1 <30% predicted) COPD.
2
At baseline, all patients had stable disease. All of them
underwent standardised spirometry according toERScriteria11
following 180 mg (2 puffs) Salbutamol. None of the subjects
were genotyped positive for alpha1-antitrypsin deficiency.usual medicine up to midnight before the visit. They were
not under oral corticosteroid therapy up to 4 weeks prior to
the visit.
Height and weight were measured and fat-free mass
(FFM) was assessed by bioelectrical impedance (BodyStat
1500); fat-free mass index (FFMI) was calculated as FFM in
kg/height squared in metres and body mass index (BMI) by
weight/height squared. Patients were assessed at baseline
for respiratory symptoms and history of exacerbations
requiring treatment with antibiotics and/or systemic
corticosteroids or requiring hospital admission in the year
prior to study entry.
To evaluate the severity, distribution of emphysema and
also to exclude non-COPD-related diseases, all subjects had
a low-dose CT scan of the chest. The CT scans were eval-
uated at the central imaging unit at the University of British
Columbia, Vancouver. The extent of emphysema was
assessed by the percentage of lung with attenuation below
950 HU using the Pulmonary Workstation 2.0 software (VIDA
Diagnostics, Iowa City, IA, USA).
The local ethics committee approved the study protocol
and patients provided written informed consent.
COPD subgroups
We examined the following subgroups of COPD: 1) Patients
with severe emphysema, defined as >10% of lung tissue
with low attenuation (950 HU) on CT, 2) Patients with
chronic bronchitis, defined by cough and phlegm for
3 months per year for at least 2 years according to the ATS-
DLD questionnaire, 3) Patients with frequent exacerba-
tions, defined as having 2 or more exacerbations in the year
prior to inclusion, 4) Patients with low body mass, defined
as body mass index <21 kg/m2, and 5) Patients with low fat-
free mass, defined as fat-free mass index <16 kg/m2 for
men and <15 kg/m2 for women.
Exhaled nitric oxide
We measured FeNO to evaluate local inflammation. Subjects
abstained from food and caffeine for 2 h, smoking for 6 h and
alcohol for 12 h prior to the measurement of FeNO using
a Niox chemiluminescence online analyser (Aerocrine, Solna,
Sweden). The analyser was calibrated according to the
manufacturer’s instructions every 14 days. After inhaling NO
free air to total lung capacity, subjects exhaled at a constant
flow rate against a resistor to collect the plateau NO
concentration. Readings were taken at five flow rates; i.e.,
10, 30, 50, 100 and 200 mL/s using the resistors supplied by
Aerocrine. The actual flow rates achievement was required
to be within 10% of the target flow rate. The exhalation
times were 20, 10, 10, 6 and 6 s, respectively at these flow
rates. Patients performed the test several times until
3 acceptable FeNO readings were achieved; we used the
mean of these 3 FeNO readings for analyses.
Mathematical modelling and statistical methods
We chose the following non-linear two-compartment
model12,13 to analyse the FeNO multiple flow rate data13:
Table 1 Characteristics of patients. Mean values and
standard deviations.
Age (years, mean  SD) 62  7
Gender (M/F) 45/46
Smoking status (ex/current) 56/35
Pack-years 45  22
BMI (kg/m2) 26  5
FFMI (kg/m2) 17  3
FEV1 (% pred.) 49  16
FEV1/FVC 45  11
Table 2 COPD subgroups and number of subjects in each
group.
Subgroups Yes No
Emphysema 61 30
Chronic bronchitis 53 38
Frequent exacerbation 37 54
Low BMI 16 75
Low FFMI 25 66
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Here the parameter Caw (NO in ppb) represents the
airway wall concentration of NO, Calv (NO in ppb) the
steady state alveolar NO concentration, and D (NO in pL or
ppb/s) the diffusing capacity of NO. FeNO is the exhaled
nitric oxide measured at the exhalation flow rate (mL/s).
This model performed best in a recent comparison
between FeNO modelling techniques.14 The aim of the
statistical analysis is to estimate differences between
clinically meaningful COPD subgroups in the values of the
model parameters Caw, Calv and D. The analysis is done in
two steps. In the first step the two-compartment model is
estimated using the data of all patients and values of Caw,
D, and Calv are predicted for each patient.
The two-compartment model was fitted using the data of
all patients simultaneously using the proc nlmixed routine
of SAS statistical software.15 Specifically we used a multi-
variate log-normal distribution to allow for individual levels
of Caw, D, and Calv. In the second step, differences in
predicted individual values of Caw, D and Calv between
COPD subgroups were assessed using linear regressionTable 3 Characteristics of patients in every subgroup. Mean va
Subgroups Gender Smoking
M/F Ex/curre
Emphysema Yes 35/26 40/21
No 20/10 16/14
Chronic bronchitis Yes 31/22 28/25
No 24/14 28/10
Frequent exacerbation Yes 15/22 24/13
No 30/24 32/22
Low BMI Yes 6/10 10/6
No 39/36 46/29
Low FFMI Yes 5/20 15/10
No 40/26 41/25analysis with adjustment for potential confounding by
patients’ age and gender.
For comparison we also applied iterative non-linear
regression, see e.g.14 to estimate the individual two-
compartment model. In contrast to our approach, this
approach estimated the individual parameters of the two-
compartment model only based on the flow rates observed
for the current patient. Some FeNO measurements were
missing or biased because the patient could not perform the
exhalation test at very high or very low exhalation flow
rates. For these patients the iterative approach is not effi-
cient and can be biased. Our approach systematically uses
the observations of the other patients, to achieve a good
approximation of the two-compartment model for patients
with missing or biased data.
We also compared COPD subgroups with respect to the
observed FeNO values at different flow rates using linear
regression with adjustment for potential confounding by
patients’ age and gender.
Results
We recruited 91 subjects, 46 women and 45 men. All of the
subjects were Caucasian and had smoked over 10 pack-
years. Most subjects (nZ 42) had severe COPD (GOLD stage
III), while 39 were in stage II and 10 in stage IV. Charac-
teristics of all of subjects are summarised in Table 1.
All subjects performed FeNO measurements at 5 flow
rates. Most of them (nZ 69) had a good quality results with
all flow rates, while 13 of them had good quality readings at
4 flow rates, 5 of them could perform just 3 and 3 of them
only 2 flow rates while one could only perform the test at
one flow rate. Subjects were classified in the 5 different
subgroups as shown in Table 2.
Table 3 shows characteristics of patients in every
subgroup as it is shown in Table 1.
In Table 4 you see mean values for all 5 flows according
to baseline demographics. FeNO at all 5 flow rates was
significantly lower in active smokers than in ex-smokers.
Table 5 shows mean values for all 5 flows according to
COPD subgroup; no consistent differences are seen.
By using the non-linear mixed-effects modelling tech-
nique we could use the entire FeNO dataset for calculating
estimated FeNO at different flow rates. Smoking had
a significant effect on Caw (p Z 0.013). This is shown inlues and standard deviations.
status Pack-Years FEV1 FEV1/FVC
nt Mean (SD) Mean (SD) Mean (SD)
46 (24) 45 (17) 42 (11)
44 (19) 58 (14) 54 (10)
49 (26) 46 (16) 43 (11)
40 (14) 54 (16) 50 (12)
48 (29) 45 (16) 44 (12)
43 (17) 52 (17) 47 (12)
52 (34) 43 (15) 40 (11)
44 (19) 51 (17) 47 (12)
46 (30) 46 (16) 43 (12)
45 (19) 51 (17) 47 (12)
Table 4 Mean values for all 5 flows according to baseline demographics.
Classes Flow rates
Flow rate 10
Mean (SD)
Flow rate 30
Mean (SD)
Flow rate 50
Mean (SD)
Flow rate 100
Mean (SD)
Flow rate 200
Mean (SD)
Current smokers 29.2 (32.1) 15.3 (12.8) 9.6 (8.8) 6.4 (5.4) 4.2 (3.7)
Ex-smokers 40.8 (30.5) 23.6 (21.1) 15.7 (12.6) 8.9 (6.9) 5.0 (3.5)
Male 42.5 (32.4) 22.8 (22.9) 13.4 (12.7) 8.1 (6.9) 4.8 (3.8)
Female 31.1 (29.3) 18.2 (13.5) 13.2 (10.3) 7.6 (5.8) 4.5 (3.3)
Gold stage II 30.9 (23.8) 15.8 (10.5) 10.6 (7.2) 6.1 (3.9) 3.9 (2.7)
Gold stage III 42.4 (37.9) 24.6 (23.5) 15.2 (13.5) 9.1 (7.6) 5.4 (4.2)
Gold stage IV 39.7 (27.4) 21.3 (19.1) 15.9 (14.9) 9.6 (7.9) 5.0 (3.7)
Table 5 Mean values for all 5 flows according to COPD subgroup.
Subgroups Flow rates
Flow rate 10
Mean (SD)
Flow rate 30
Mean (SD)
Flow rate 50
Mean (SD)
Flow rate 100
Mean (SD)
Flow rate 200
Mean (SD)
With severe emphysema 38.1 (31.6) 21.1 (19.2) 14.2 (12.1) 8.3 (6.7) 4.8 (3.6)
Without severe emphysema 33.3 (30.9) 18.7 (17.4) 11.5 (10.2) 6.9 (5.6) 4.3 (3.5)
With chronic bronchitis 33.4 (31.0) 18.3 (14.5) 11.5 (9.3) 7.0 (5.2) 4.4 (3.5)
Without chronic bronchitis 41.1 (31.5) 21.8 (21.9) 14.8 (12.3) 8.4 (6.9) 4.6 (3.4)
Frequent exacerbators 41.5 (33.2) 24.2 (24.4) 14.5 (14.5) 8.7 (7.6) 5.2 (4.2)
No exacerbation 33.6 (29.9) 17.7 (12.6) 12.5 (9.0) 7.3 (5.4) 4.2 (3.1)
Low BMI 35.4 (24.9) 18.0 (9.1) 11.1 (6.4) 6.7 (3.5) 4.4 (2.8)
Normal BMI 37.0 (32.8) 20.9 (20.1) 13.8 (12.3) 8.1 (6.8) 4.6 (3.6)
Low FFMI 45.7 (38.5) 25.6 (26.5) 13.7 (14.1) 8.3 (7.5) 5.6 (4.4)
Normal FFMI 33.4 (27.8) 18.6 (14.8) 13.2 (10.5) 7.7 (6.0) 4.4 (3.3)
FeNO and COPD subgroups 1341Fig. 1 where the modelled FeNO rates are depicted acc-
ording to smoking status. We also found borderline statis-
tically significant effects of gender on both D and Calv
(p Z 0.049 and 0.048).
The differences between D, Caw and Calv in the
6 different COPD subgroups are shown in Table 6 by the ratio
between estimated levels, 95% confidence intervals and p
values. None of the 3 parameters differed significantly
depending on COPD subgroup. We found similar results when
applying the standard iterative regression analysis.Figure 1 Modelled FeNO values at 5 different flows for all
patients according to current smoking status.Discussion
In this study we found that modelled airway parameters
derived from multiple flow FeNO measurements did not
differ significantly between patients characterised
according to 5 clinically relevant subgroups. The subgroups
included frequent exacerbators and subjects with chronic
bronchitis where severe airway inflammation was likely to
be overrepresented as well as patients with CT-defined
emphysema where alveolar inflammation is more likely
present than in patients without CT-defined emphysema.
Our findings thus weaken the prospects of using multiple
FeNO as a non-invasive biomarker in COPD.
Inflammation is a hallmark of COPD1 and we picked
several subgroups where inflammation should play a major
role. Pulmonary and systemic inflammation in COPD appears
to increase with disease progression and during an exacer-
bation.16,17 An increased recruitment of eosinophils duringexacerbation has been described18,19 which might affect
FeNO and its derived parameters but this has not been
looked at in detail. Previous studies using measurement of
FeNO at a single flow rate of 50 mL/s showed that FeNO was
significantly higher during an exacerbation7,20 but no rela-
tionship was found between exacerbation frequency in the
Table 6 Levels of D, Caw and Calv in different COPD
subgroups, shown as the ratio between estimated levels.
95% confidence intervals (95% CI) and p values are shown.
D Caw Calv
Severe emphysema
Yes/No ratio 0.83 1.39 1.19
95% CI [0.62; 1.11] [0.89; 2.15] [0.9; 1.55]
p 0.21 0.15 0.22
Chronic bronchitis
Yes/No ratio 1.08 0.80 0.93
95% CI [0.82; 1.43] [0.53; 1.22] [0.72; 1.2]
p 0.56 0.31 0.58
Frequent
exacerbation
Yes/No ratio 1.05 1.09 0.95
95% CI [0.8; 1.38] [0.71; 1.66] [0.73; 1.23]
p 0.72 0.69 0.68
Low BMI
Low/normal ratio 0.91 1.00 1.08
95% CI [0.65; 1.29] [0.59; 1.7] [0.79; 1.51]
p 0.62 0.99 0.61
Low FFMI
Low/high ratio 1.05 0.97 0.95
95% CI [0.77; 1.44] [0.6; 1.58] [0.71; 1.29]
p 0.77 0.89 0.77
Figure 2 Modelled FeNO values at 5 different flows for patients in
bronchitis (A), severe emphysema (B), frequent exacerbations (C)
(FFMI).
1342 N. Bazeghi et al.previous year and the mean FeNO at stable condition.21
Patients with chronic bronchitis have also found to have
more inflammation in and around their bronchial glands
although the number of eosinophils and mast cells were not
elevated.22 Both chronic bronchitis and a history of exacer-
bations were frequently seen in our patients but these
features did not reflect in FeNO, neither in levels at the
5 flow rates nor in the derived parameters Fig. 2.
Patients with emphysema have increased inflammation
at the alveolar level.19,23,24 We had anticipated that Calv
would reflect inflammation at the alveolar level and thus
could be used as a marker of emphysema; however, this
was not the case in our study. This could be the result of
Calv being a marker of small airway inflammation rather
than alveolar inflammation8 but it could also reflect the
fact that Calv is a highly variable measurement.14 Patients
with emphysema may be more prone to have systemic
inflammation and more systemic manifestations of
COPD.8,25,26 Low BMI and FFMI are poor prognosis in COPD
patients. We looked at low body weight/low fat-free mass
as systemic manifestations of COPD and found that loss of
body mass/lean body mass did not affect FeNO at different
flow rates or any of the derived parameters.
FeNO has the potential of being a non-invasive
biomarker and like exhaled breath condensate could
provide a signal derived more directly from the organs
under study than e.g. markers in systemic blood. Otherthe study divided according to presence or absence of chronic
, low body mass index (BMI) (D), and low fat-free mass index
FeNO and COPD subgroups 1343studies on multiple flows FeNO have shown differences in
the derived parameters with respect to treatment with
inhaled corticosteroids and smoking status. Different
studies have shown that inhaled corticosteroids decrease
bronchial NO flux but has no effect on alveolar NO
concentration in patients with COPD.27,28 Furthermore, it
has been reported that smoking reduces FeNO at flow rate
50 and Caw in multiple flow FeNO.14,29 We found signifi-
cantly lower Caw values in smokers compared with ex-
smokers in agreement with previously published data.
Our study has weaknesses. Patients have quite different
level of FeNO in differentflow rates, and noneof the available
information can explain this. In other words, we are missing
important factors that could explain why the FeNO values
observed for somepatientsareveryhighorvery lowcompared
tomostof theotherpatients.Weneed further investigation to
learn about some other factors, which can strongly affect
FeNO values. The majority of our patients were GOLD stage
3and it is possible thatmarkers suchas FeNOmayhavegreater
value in early disease where inflammation is more likely to
reflect the disease process rather than the consequences of
long-lasting disease. Also, including only ex-smokers could
potentially have increased our chance of finding differences;
however, our patients’ composition reflects real life practice.
There was also significant overlap between the different
subgroups studied. It may be possible to select patients that
more clearly fall into categories without much overlap.
However, it is unlikely that COPDcanbe separated into groups
with clear characteristics. In real life, patients have over-
lapping characteristics and this is what our study reflects.
The strengths of the current study include relatively
large sample size, the rigorous and standardized measure-
ments as well as the advanced statistical modelling which
allowed us to include also the data of subjects that were
unable to provide readings at all 5 flow rates.
When a potential biomarker does not differentiate
between disease subgroups, it seems fair to question if the
selection of subgroups is adequate, as poor selection will
affect the apparent validity of the biomarker. Our
subgroups were chosen on the basis of clinical e and to
some extent historical e separation of COPD patients. It is
possible that FeNO may be useful for characterising
subgroups with inflammation that are not captured using
our subgrouping. To some extent, the recent findings of
Dummer et al. suggest that this may be the case.30
However, in conclusion, our results show limitations of
using NO measurement to distinguish different COPD
subgroups. Our findings weaken the prospects of using
multiple FeNO as a non-invasive biomarker in COPD.
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